Consultation record

Submissions accepted — page 10

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

735 documents · page 10 of 25

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-PRINT-AND-AR/007	Draft print and archival format for Institute documents	Dr Odalys Thorsby-Nakamura	Absence of evidence is presented in a form a reader will take as negative evidence
DRAFT-PRINT-AND-AR/008	Draft print and archival format for Institute documents	Georgiana Zimmerthal	No term limit applies to membership of the assessment committee
DRAFT-PRINT-AND-AR/009	Draft print and archival format for Institute documents	Dr Jozef Brandvold-Achterberg	Disagreement within the assessment committee is not visible
DRAFT-PRINT-AND-AR/012	Draft print and archival format for Institute documents	Dr Fitzwilliam Danquah-Öberg	Quantitative claims are reproduced without the method that produced them
DRAFT-PRINT-AND-AR/013	Draft print and archival format for Institute documents	Kamila Ubertini	The position of a contributor who withdraws consent is not stated
DRAFT-PRINT-AND-AR/015	Draft print and archival format for Institute documents	Ivo Mountstephen	A reader who acted on a document is not told when it is corrected
DRAFT-PRINT-AND-AR/017	Draft print and archival format for Institute documents	Kolawole Jankowiak-Osei	The policy does not say who may make a submission
DRAFT-PRINT-AND-AR/018	Draft print and archival format for Institute documents	Anselm Mountstephen	The policy does not say what happens to a document the Institute is asked to remove
DRAFT-CERTAINTY-IN/002	Draft certainty index	Quentin Whitmarsh-Obi	The same quantity is presented differently in two series
DRAFT-CERTAINTY-IN/005	Draft certainty index	Dr Emiliana Ollerenshaw	Indications for which compounds are supplied are absent from the set
DRAFT-CERTAINTY-IN/006	Draft certainty index	Anselm Mountstephen	An identifier that encodes the document type will have to change when the type does
DRAFT-CERTAINTY-IN/007	Draft certainty index	Professor Bartolomeu Nkosi-Lindegaard	The identifier encodes the document type, which is a property that can change
DRAFT-CERTAINTY-IN/008	Draft certainty index	Dr Jozef Brandvold-Achterberg	Absence of evidence is presented in a form a reader will take as negative evidence
DRAFT-CERTAINTY-IN/009	Draft certainty index	Ivo Mountstephen	A withdrawn document should not simply disappear
DRAFT-CERTAINTY-IN/012	Draft certainty index	Dr Vittoria Quintanilha	A section with nothing in it is emitted with a heading and a sentence saying so
DRAFT-CERTAINTY-IN/013	Draft certainty index	Dr Yusuf Whitmarsh-Obi	A document does not show what draws on it
DRAFT-AMYCRETIN-MO/001	Draft monograph: amycretin	Dr Lorcan Trelawney	The absence of a rare harm in the trial set is presented as reassurance
DRAFT-AMYCRETIN-MO/003	Draft monograph: amycretin	Dr Eamon Immelmann	The analytical section assumes a reference standard that is not generally available
DRAFT-AMYCRETIN-MO/004	Draft monograph: amycretin	Dr Vasilisa Immelmann	The indication table mixes approved indications with uses for which the compound is merely supplied
DRAFT-AMYCRETIN-MO/005	Draft monograph: amycretin	Dr Ndidi Ravensworth-Ilunga	Registered trials that never reported are absent from the monograph
DRAFT-AMYCRETIN-MO/007	Draft monograph: amycretin	Dr Lorcan Zaleski-Mbeki	Local reactions are omitted from the adverse-event table because the trials reported them separately
DRAFT-AMYCRETIN-MO/010	Draft monograph: amycretin	Dr Wolfram Kaltenbach-Mensah	What happens to weight after the compound is stopped is not in the assessed outcomes
DRAFT-AMYCRETIN-MO/011	Draft monograph: amycretin	Dr Kamila Glendinning-Uche	Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as…
DRAFT-AMYCRETIN-MO/012	Draft monograph: amycretin	Dr Hyacinth Drakeford-Amadi	Doses are expressed in units that differ between sections
DRAFT-AMYCRETIN-MO/015	Draft monograph: amycretin	Dr Constança Glendinning-Uche	The same concept is given three different names in one document
DRAFT-AMYCRETIN-MO/016	Draft monograph: amycretin	Dr Zdenka Nyquist-Obiora	The pharmacokinetic section does not connect half-life to the dosing schedule
DRAFT-5-AMINO-1MQ-/001	Draft monograph: 5-amino-1MQ	Dr Odalys Thorsby-Nakamura	The certainty rating for the principal assessed outcome cannot be traced to the contributing trials
DRAFT-5-AMINO-1MQ-/002	Draft monograph: 5-amino-1MQ	Dr Vittoria Quintanilha	Open-label extension data are presented alongside randomised data without distinction
DRAFT-AOD-9604-MON/001	Draft monograph: AOD-9604	Dr Adaeze Underhill-Okafor	Absence of evidence is presented in a form a reader will take as negative evidence
DRAFT-AOD-9604-MON/002	Draft monograph: AOD-9604	Dr Rurik Underhill-Okafor	Nothing is said about impaired renal or hepatic clearance

page 10 of 25